• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    70 Biggest Movers From Friday

    5/31/22 5:15:40 AM ET
    $ACB
    $ACET
    $ACHR
    $ACLX
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACB alert in real time by email

    Gainers

    • Avadel Pharmaceuticals plc (NASDAQ:AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for experimental narcolepsy drug.
    • Oncternal Therapeutics, Inc. (NASDAQ:ONCT) jumped 88.1% to settle at $1.54. Oncternal Therapeutics presented updated interim data for zilovertamab in combination with ibrutinib at ASCO 2022.
    • SIGA Technologies, Inc. (NASDAQ:SIGA) climbed 41.9% to close at $13.68. European Union has agreed to buy Bavarian Nordic's Imvanex, Tecoviriat from Siga in the US.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) rose 39.3% to close at $2.87 after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and an $8 price target.
    • Imperial Petroleum Inc. (NASDAQ:IMPP) gained 38.4% to close at $0.5480. Imperial Petroleum announced agreement to acquire two Suezmax tankers for $46.8 million.
    • JE Cleantech Holdings Limited (NASDAQ:JCSE) surged 34.8% to close at $14.99.
    • Merus N.V. (NASDAQ:MRUS) jumped 32.6% to close at $18.53. Merus announced the publication of abstract of Zenocutuzumab in NRG1-fusion (NRG1+) cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
    • Farfetch Limited (NASDAQ:FTCH) jumped 26.7% to close at $9.73 following Q1 results.
    • Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) surged 25.7% to close at $20.88.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) jumped 25.5% to settle at $0.7530.
    • Icosavax, Inc. (NASDAQ:ICVX) gained 25.4% to close at $10.23. Icosavax recently posted a Q1 loss of $0.60 per share.
    • Red Robin Gourmet Burgers, Inc. (NASDAQ:RRGB) jumped 25.1% to close at $10.77 after the company reported better-than-expected Q1 results.
    • MoonLake Immunotherapeutics (NASDAQ:MLTX) gained 24.6% to close at $6.38. MoonLake Immunotherapeutics recently dosed first patient in the Phase 2 clinical trial evaluating sonelokimab, for patients with moderate-to-severe hidradenitis suppurativa (HS).
    • Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) gained 24.4% to close at $0.75.
    • MiNK Therapeutics, Inc. (NASDAQ:INKT) gained 22.8% to close at $1.67. MiNK Therapeutics recently posted a Q1 loss of $0.23 per share.
    • SoundHound AI, Inc. (NASDAQ:SOUN) surged 21.3% to close at $7.91.
    • Applied Blockchain, Inc. (NASDAQ:APLD) gained 21.1% to settle at $4.60.
    • 111, Inc. (NASDAQ:YI) gained 20.8% to close at $1.92.
    • Ontrak, Inc. (NASDAQ:OTRK) gained 20.6% to close at $1.93.
    • Arcellx, Inc. (NASDAQ:ACLX) rose 20.6% to close at $11.55.
    • Enochian Biosciences, Inc. (NASDAQ:ENOB) jumped 20.5% to close at $5.35. The co-founder of Enochian Biosciences was arrested Wednesday following a two-year investigation into a man who was kidnapped and found dead in January 2018.
    • Super Group (SGHC) Limited (NYSE:SGHC) gained 19.7% to settle at $7.22.
    • Rent the Runway, Inc. (NASDAQ:RENT) jumped 19.6% to close at $4.40.
    • Vivos Therapeutics, Inc. (NASDAQ:VVOS) rose 19.1% to settle at $1.87. Vivos Therapeutics recently posted a Q1 loss of $0.26 per share.
    • Zymergen Inc. (NASDAQ:ZY) jumped 19% to close at $1.38.
    • Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) gained 18.8% to close at $1.1350.
    • Carver Bancorp, Inc. (NASDAQ:CARV) surged 18.5% to close at $11.58.
    • Archer Aviation Inc. (NYSE:ACHR) jumped 18.5% to settle at $4.10.
    • Tabula Rasa HealthCare, Inc. (NASDAQ:TRHC) surged 18.4% to close at $3.86.
    • AMC Entertainment Holdings, Inc. (NYSE:AMC) gained 18% to settle at $14.43.
    • Express, Inc. (NYSE:EXPR) surged 17.7% to close at $3.00. Express recently reported better-than-expected Q1 sales results and raised its FY22 guidance.
    • Amyris, Inc. (NASDAQ:AMRS) jumped 17.6% to close at $2.67.
    • Novavax, Inc. (NASDAQ:NVAX) gained 17.5% to settle at $55.29. B of A Securities recently initiated coverage on the stock with an Underperform rating.
    • Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) climbed 17.1% to close at $5.88 after gaining over 7% on Thursday. Concert Pharmaceuticals recently announced topline results from its Phase 3 THRIVE-AA1 trial of CTP-543 in adult patients with moderate to severe alopecia areata (AA).
    • Renalytix Plc (NASDAQ:RNLX) gained 17% to close at $4.19.
    • PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) shares gained 16.1% to close at $15.33. PMV Pharmaceuticals announced initial PC14586 Phase 1 clinical data to be presented at the 2022 American Society of Clinical Oncology Annual Meeting June 7.
    • Houston American Energy Corp. (NASDAQ:HUSA) gained 16.1% to close at $3.76.
    • Karooooo Ltd. (NASDAQ:KARO) rose 14.9% to close at $28.95.
    • Opendoor Technologies Inc. (NASDAQ:OPEN) gained 14.8% to close at $7.49.
    • Adicet Bio, Inc. (NASDAQ:ACET) rose 14.5% to close at $11.75 after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma.
    • Omega Therapeutics, Inc. (NASDAQ:OMGA) rose 14% to settle at $2.53.
    • Dell Technologies Inc. (NYSE:DELL) climbed 12.9% to close at $49.58 after the company reported better-than-expected Q1 results.
    • Ulta Beauty, Inc. (NASDAQ:ULTA) gained 12.5% to close at $425.08 after the company reported better-than-expected Q1 results and raised FY22 net sales guidance.
    • Solo Brands, Inc. (NYSE:DTC) shares gained 8.3% to close at $4.94. Solo Brands recently reported worse-than-expected Q1 sales results.

     

     

    Losers

    • Performance Shipping Inc. (NASDAQ:PSHG) shares dipped 63.6% to close at $0.6632 on Friday after the company announced the pricing of an underwritten public offering of 7,620,000 units at $1.05 per unit. Each unit consists of one common share and one Class A warrant to purchase one common share.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares dipped 53.6% to close at $7.02 after the company reported results from its C-144-01 clinical study in patients with advanced melanoma. Piper Sandler and Chardan Capital lowered their price targets on the stock.
    • SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) fell 40.5% to close at $18.36 after the company announced initial clinical data from the Phase 1/2 study evaluating nirogacestat.
    • Aurora Cannabis Inc. (NASDAQ:ACB) dropped 38.5% to close at $1.68 after the company announced upsized bought deal financing of $150 million.
    • MSP Recovery, Inc. (NASDAQ:MSPR) dropped 32.3% to close at $1.74.
    • Mirati Therapeutics, Inc. (NASDAQ:MRTX) fell 31.9% to close at $39.81. Mirati Therapeutics reported positive results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib 600 mg BID in patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least one prior systemic therapy.
    • CASI Pharmaceuticals, Inc. (NASDAQ:CASI) dipped 28.9% to settle at $0.37. Casi Pharmaceuticals announced a 1-for-10 reverse stock split effective June 1.
    • I-Mab (NASDAQ:IMAB) fell 26.9% to close at $8.27 as the company reported preliminary data of its ongoing Phase 2 clinical trial (NCT04322006) with uliledlimab, a differentiated CD73 antibody, and its global clinical development plan.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) dipped 26.7% to close at $2.83.
    • Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA) fell 26.3% to close at $2.50.
    • Mesa Royalty Trust (NYSE:MTR) dipped 26.3% to close at $17.50.
    • Instil Bio, Inc. (NASDAQ:TIL) dropped 24.3% to close at $6.00 as the company reported the IND clearance of first CoStAR-TIL program, ITIL-306, designed to enhance activity in the tumor microenvironment.
    • Quanergy Systems, Inc. (NYSE:QNGY) dipped 22.3% to settle at $0.5441.
    • Bright Green Corporation (NASDAQ:BGXX) fell 21.7% to close at $6.18.
    • Bon Natural Life Limited (NASDAQ:BON) fell 20.8% to settle at $3.77.
    • The Very Good Food Company Inc. (NASDAQ:VGFC) dipped 18.7% to close at $0.2582. The Very Good Food Company recently announced it increased retail distribution across Canada with Loblaw Companies.
    • UTStarcom Holdings Corp. (NASDAQ:UTSI) fell 18.3% to close at $0.6128.
    • ToughBuilt Industries, Inc. (NASDAQ:TBLT) dropped 16.7% to close at $5.00.
    • Genocea Biosciences, Inc. (NASDAQ:GNCA) declined 16.3% to settle at $0.0620. Genocea Biosciences recently announced it is winding down operations and delisting from NASDAQ.
    • Guardion Health Sciences, Inc. (NASDAQ:GHSI) dropped 15.3% to close at $0.1727. Guardion Health Sciences recently posted a Q1 loss of $0.07 per share.
    • Creatd, Inc. (NASDAQ:CRTD) fell 14.1% to close at $1.10.
    • SciSparc Ltd. (NASDAQ:SPRC) fell 13.8% to close at $2.87. SciSparc announced pricing of $10 million private placement priced at-the-market.
    • Big Lots, Inc. (NYSE:BIG) declined 12.1% to close at $26.94 after the company reported Q1 EPS results down from last year and worse-than-expected sales results.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) dropped 11.7% to close at $0.7681.
    • Citi Trends, Inc. (NASDAQ:CTRN) dropped 11.4% to close at $29.76. Citi Trends recently reported better-than-expected Q1 adjusted EPS and sales results.
    • Workday, Inc. (NASDAQ:WDAY) fell 5.6% to close at $158.79 after the company reported worse-than-expected Q1 EPS results.
    Get the next $ACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACB
    $ACET
    $ACHR
    $ACLX

    CompanyDatePrice TargetRatingAnalyst
    Aurora Cannabis Inc.
    $ACB
    1/27/2026Buy
    Canaccord Genuity
    Arcturus Therapeutics Holdings Inc.
    $ARCT
    1/23/2026$20.00Buy
    Roth Capital
    Tempest Therapeutics Inc.
    $TPST
    1/22/2026$11.00Neutral → Buy
    H.C. Wainwright
    Ulta Beauty Inc.
    $ULTA
    1/21/2026$790.00Outperform → Strong Buy
    Raymond James
    Dell Technologies Inc.
    $DELL
    1/15/2026$148.00Equal Weight → Overweight
    Barclays
    Ulta Beauty Inc.
    $ULTA
    1/14/2026$700.00Hold
    Jefferies
    Dell Technologies Inc.
    $DELL
    1/13/2026$165.00Buy
    Goldman
    Workday Inc.
    $WDAY
    1/12/2026$238.00Neutral
    Goldman
    More analyst ratings

    $ACB
    $ACET
    $ACHR
    $ACLX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Red Robin Gourmet Burgers Inc.

    SCHEDULE 13G/A - RED ROBIN GOURMET BURGERS INC (0001171759) (Subject)

    2/6/26 6:39:11 PM ET
    $RRGB
    Restaurants
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Dell Technologies Inc.

    SCHEDULE 13G/A - Dell Technologies Inc. (0001571996) (Subject)

    2/6/26 4:40:24 PM ET
    $DELL
    Computer Manufacturing
    Technology

    Tempest Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Changes in Control of Registrant

    8-K - Tempest Therapeutics, Inc. (0001544227) (Filer)

    2/6/26 4:12:27 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $ACET
    $ACHR
    $ACLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by CEO and President Angel Matthew

    4 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    2/6/26 4:26:13 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Angel Matthew claimed ownership of 8,268,495 shares (SEC Form 3)

    3 - Tempest Therapeutics, Inc. (0001544227) (Issuer)

    2/6/26 4:24:53 PM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Mccamish Mark Anthony gifted 67,025 units of Ordinary Shares and received a gift of 67,025 units of Ordinary Shares (SEC Form 4)

    4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)

    2/6/26 4:10:10 PM ET
    $AVDL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $ACET
    $ACHR
    $ACLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

    SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and ta

    2/5/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cartrack Partners With Schmitz Cargobull to Deliver Integrated Fleet Telematics Solution for Trailers

    Fleet operators gain secure, real-time access to connected trailer data with seamless integration into Cartrack's Software-as-a-Service (SaaS) fleet platform. Cartrack, a leading global mobility solutions provider and subsidiary of Karooooo Limited (NASDAQ:KARO), has entered into a partnership with Schmitz Cargobull, Europe's premier manufacturer of semi-trailers and a trailblazer in digital trailer connectivity. The partnership enables seamless integration of TrailerConnect® telematics data into Cartrack's platform, giving transport operators real-time visibility and complete control over their fleet operations, with the integration taking place automatically when a customer opts in an

    2/5/26 8:57:00 AM ET
    $KARO
    Computer Software: Prepackaged Software
    Technology

    Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbreaking FDA-Cleared Allergy and Sleep Technologies

    Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' extensive national network of over 2,00

    2/5/26 8:45:00 AM ET
    $VVOS
    Medical/Dental Instruments
    Health Care

    $ACB
    $ACET
    $ACHR
    $ACLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Genmab A/S bought $79,098,068 worth of shares (815,444 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/29/25 5:16:48 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $27,008,777 worth of shares (278,441 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/22/25 5:15:45 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Genmab A/S bought $26,340,059 worth of shares (271,547 units at $97.00) (SEC Form 4)

    4 - Merus N.V. (0001651311) (Issuer)

    12/18/25 5:54:51 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $ACET
    $ACHR
    $ACLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    December 6, 2024 - FDA Roundup: December 6, 2024

    For Immediate Release: December 06, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA published the draft guidance, “Expedited Program for Serious Conditions — Accelerated Approval of Drugs and Biologics,” which proposes updates to certain agency policies and procedures regarding accelerated approval. Topics addressed by this

    12/6/24 3:09:02 PM ET
    $MRUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACB
    $ACET
    $ACHR
    $ACLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Aurora Cannabis

    Canaccord Genuity initiated coverage of Aurora Cannabis with a rating of Buy

    1/27/26 9:29:20 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Roth Capital initiated coverage on Arcturus Therapeutics with a new price target

    Roth Capital initiated coverage of Arcturus Therapeutics with a rating of Buy and set a new price target of $20.00

    1/23/26 8:16:17 AM ET
    $ARCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tempest Therapeutics upgraded by H.C. Wainwright with a new price target

    H.C. Wainwright upgraded Tempest Therapeutics from Neutral to Buy and set a new price target of $11.00

    1/22/26 8:24:05 AM ET
    $TPST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACB
    $ACET
    $ACHR
    $ACLX
    Leadership Updates

    Live Leadership Updates

    View All

    Workiva Announces Two New Appointments to Board of Directors

    Company Appoints Former Cisco and Autodesk CFO Scott Herren and Former Workday Co-President, CFO, and EVP Mark Peek Workiva Inc. (NYSE:WK), a leading, AI-powered platform for trust, transparency, and accountability, today announced the appointment of two new independent directors to its Board of Directors. Scott Herren is the former EVP and Chief Financial Officer of Cisco and current Board member and Audit Committee Chair at Rubrik (NYSE:RBRK). Mark Peek is a former EVP, CFO, and Co-President of Workday (NASDAQ:WDAY) and currently sits on the Board of Directors for SentinelOne (NYSE:S) and Trimble (NASDAQ:TRMB). "We are pleased to welcome two highly experienced SaaS leaders to our Boar

    1/28/26 4:05:00 PM ET
    $RBRK
    $S
    $TRMB
    Computer Software: Prepackaged Software
    Technology
    Industrial Machinery/Components
    Industrials

    LAIKA Partners With Fathom Entertainment for Domestic Distribution and FilmNation Entertainment for International Sales on Wildwood

    Confirms October 23, 2026 U.S. Release Date LAIKA, the studio behind Coraline and ParaNorman, announced today that it has partnered with Fathom Entertainment for U.S. theatrical distribution and FilmNation Entertainment for international sales on its upcoming stop-motion feature film Wildwood. The film will open in theaters nationwide on October 23, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120938376/en/LAIKA Names Fathom Entertainment as US Distributor and FilmNation Entertainment for International Sales for "Wildwood" coming October 23, 2026 The announcement reflects a new phase for LAIKA, as the studio expands

    1/20/26 11:15:00 AM ET
    $AMC
    $CNK
    Movies/Entertainment
    Consumer Discretionary

    Workday to Invest CAD $1 Billion in Canada Over Five Years

    Investment to Fuel the Growth of Workday's Canadian Business and Support Workday's Rapidly Growing Canadian Customer Base Company Joins With Glowing Hearts Reservist Registry as Part of Ongoing Efforts to Support Local Communities in Canada PLEASANTON, Calif., Jan. 20, 2026 /PRNewswire/ -- Workday, Inc.  (NASDAQ:WDAY), the enterprise AI platform for managing people, money, and agents, today announced its plans to invest CAD $1 billion in Canada over the next five years. The multi-year investment demonstrates Workday's commitment to growing in Canada, including plans to further develop local tech talent, strengthen local customer support, and give back to Canadian communities through particip

    1/20/26 8:00:00 AM ET
    $WDAY
    EDP Services
    Technology

    $ACB
    $ACET
    $ACHR
    $ACLX
    Financials

    Live finance-specific insights

    View All

    Aurora Cannabis Announces Fiscal 2026 Third Quarter Results

    NASDAQ | TSX: ACB Expands YoY Total Net Revenue1 by 7% to $94.2 million, with Global Medical Cannabis Net Revenue1 Increasing by 12% to a Record $76.2 millionDelivers Adjusted EBITDA1 of $18.5 million and Adjusted Net Income1 of $7.2 millionGenerates Free Cash Flow1 of $15.5 million Maintains Strong Balance Sheet with $154.4 million of Cash2 and Short-Term Investments, and a Debt-Free Cannabis Business2EDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ:ACB) (TSX:ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the third quarter 2026 period ending December 31, 2025.

    2/4/26 7:00:00 AM ET
    $ACB
    Medicinal Chemicals and Botanical Products
    Health Care

    Workday Announces Date of Fiscal 2026 Fourth Quarter and Full Year Financial Results on February 24th, 2026

    PLEASANTON, Calif., Feb. 3, 2026 /PRNewswire/ -- Workday, Inc. (NASDAQ:WDAY), the enterprise AI platform for managing people, money, and agents, will announce its fiscal 2026 fourth quarter and full year financial results after market close on Tuesday, February 24, 2026. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to review its financial results and business outlook. A live webcast of the event will be available on the Workday Investor Relations site. The replay of the webcast will be available for a minimum of 90 days after the c

    2/3/26 8:30:00 AM ET
    $WDAY
    EDP Services
    Technology

    Opendoor 4Q25 Financial Open House: Opendoor to Report Fourth Quarter and Full Year 2025 Financial Results on February 19th, 2026

    SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Opendoor Technologies Inc. ("Opendoor") (NASDAQ:OPEN) today announced that it will report fourth quarter and full year 2025 financial results for the period ended December 31, 2025 following the close of the market on Thursday, February 19, 2026. Modernizing Investor AccessOn February 19, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company's business and financial results. We believe in building in the open. The Financial Open House replaces the traditional earnings conference call with a video event, including a live segment for shareholder Q&A. Shareholder Q&AWe invi

    1/30/26 9:00:00 AM ET
    $OPEN
    Real Estate
    Finance

    $ACB
    $ACET
    $ACHR
    $ACLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

    SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

    12/12/24 7:22:30 PM ET
    $KAVL
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by Carver Bancorp Inc.

    SC 13D/A - CARVER BANCORP INC (0001016178) (Subject)

    12/12/24 5:00:53 PM ET
    $CARV
    Savings Institutions
    Finance

    SEC Form SC 13G filed by PMV Pharmaceuticals Inc.

    SC 13G - PMV Pharmaceuticals, Inc. (0001699382) (Subject)

    12/12/24 12:29:41 PM ET
    $PMVP
    Biotechnology: Pharmaceutical Preparations
    Health Care